The week in pharma: action, reaction and insight – week to January 17

19 January 2025

By Barbara Obstoj-Cardwell. Editor

Last Friday saw the USA’s Center for Medicare and Medicaid Services (CMS) announce the selection of 15 new drugs covered under Medicare Part D for price negotiations. US antiviral giant Gilead Sciences is broadening its therapeutics focus with a deal for LEO Pharma’s small molecule oral STAT6 program in the area of inflammatory diseases.US healthcare giant Johnson & Johnson announced its planned $14.6 billion acquisition of Intra-Cellular Therapies, along with its already marketed CNS drug Caplyta. USA-based Keros Therapeutics revealed it is termination another Phase II study of its pulmonary arterial hypertension (PAH) candidate cibotercept. Also, Italy’s Newron Pharmaceuticals out-licensed its CNS drug evenamide to South Korea’s Myung In Pharma, having just recently licensed the drug to EA Pharma, a unit of Japan’s Eisai.

CMS price controls: 15 for 2027

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK